Öйú365betÖÐÎĹÙÍø

Join this ACS Publications webinar to delve into three pivotal studies that have the potential to revolutionize therapeutic approaches and drug delivery systems. Hear from Dr. Sergio Martin Saldaña, Ms. Thu A. Hoang, and Dr. John Gleeson, winners of the 2025 Molecular Pharmaceutics Early Career Best Paper Awards.

Speakers

• Ms. Thu A. Hoang, PhD Candidate, Monash University, Australia, Thu Hoang is currently completing her PhD under the supervision of Associate Professor Natalie Trevaskis and Professor Joseph Nicolazzo at Monash University. Her research focuses on the development of a novel lymph cannulation method to collect and analyze the composition of cervical lymph draining from the brain in anaesthetized rat models and evaluating the lymphatic drainage of model therapeutics in health and neuroinflammation. She completed her Bachelor of Pharmacy (with Honours) at Monash University in 2014. She also works as a clinical pharmacist at the Royal Women’s Hospital in Melbourne, Australia.

• Dr. John Gleeson, Associate Principal Scientist in Exploratory Biopharmaceutics, Merck, Inc., United States, Dr. John Gleeson is an Associate Principal Scientist in Exploratory Biopharmaceutics within Merck’s Pharmaceutical Science and Clinical Supply division. At Merck, John supports the pre-clinical to clinical development of formulations for both small molecule and peptide programs. John leads efforts on intestinal permeability models and establishing IVIVC. John earned his PhD in Drug Delivery from University College Dublin under the supervision of Prof. David Brayden.

• Dr. Sergio Martin Saldaña, Researcher, Instituto de Ciencia y Tecnología de Polímeros - CSIC, Spain, My career has always been at the frontier of Biology and Materials Science. I began my research journey working on potential otoprotectors against cisplatin (CDDP)-induced ototoxicity. The main goal of my PhD was to pursue the development of polymeric nanoparticles capable of efficiently carrying hydrophobic drugs, and reach the inner ear to palliate the ototoxic effect of CDDP. Moreover, we described, for the first time, the presence of cannabinoid receptor 2, CB2, in the inner ear, showing an up-regulation of gene expression in animals treated with CDDP, suggesting its potential as a therapeutic target.

-Prof. Lynne S. Taylor, Editor-in-Chief, Molecular Pharmaceutics, Editor-in-Chief, Molecular Pharmaceutics, Retter Professor of Pharmacy, Purdue University College of Pharmacy, United States, Dr. Lynne S. Taylor earned her Bachelor of Pharmacy from the University of Bath and her Ph.D. from the University of Bradford. Subsequently, she was appointed a Postdoctoral Research Associate position at the University of Wisconsin � Madison before joining AstraZeneca as an Associate Principal Scientist in 1998. Dr. Taylor joined Purdue University in 2003 and currently serves as the Retter Professor of Pharmacy in the Department of Industrial and Physical Pharmacy.